Managing High Risk Vs. Low Risk Thyroid Cancer

Newswise — A panel of thyroid cancer experts will discuss the management of high and low risk thyroid cancers in a panel session held Friday, January 23, 2009 from 11:00 a.m. until noon in Americana 3, 2rd level, at the American Thyroid Association's National Thyroid Cancer Workshop II to be held January 23 " 24, 2009 at the Loews Miami Beach Hotel, Miami Beach, Florida.

Moderated by David Cooper, M.D., professor of medicine at the Johns Hopkins University School of Medicine, the panel will discuss ATA Thyroid Nodule And Cancer Management Guidelines for high and low risk thyroid cancers, including staging and treatment modalities using case studies.

The discussion, featuring panel members Gerard M. Doherty, M.D., University of Michigan, Stephanie L. Lee, M.D., Ph.D, Boston University, and Furio Pacini, M.D., University of Siena, Italy, will focus on four patient case studies and treatment questions posed for each that will include: What is the appropriate radioiodine dose for low risk patients?; Should ablation be performed following withdrawal from thyroid hormone therapy?; What is the role of recombinant TSH in remnant ablation? What is the role of prophylactic central neck dissection in thyroid cancer surgery?

Members of the media can find additional information at the ATA's Media Room, the Lucina Room, 3rd floor, Loews Miami Beach Hotel.

The American Thyroid Association (ATA) is the lead organization in promoting thyroid health and understanding thyroid biology. The ATA values scientific inquiry, clinical excellence, public service, education, collaboration, and collegiality. ATA members are physicians and scientists who work to enhance the understanding of thyroid physiology and pathophysiology, improve diagnosis and treatment of thyroid diseases, and promote the education of physicians, patients, and the public about thyroid cancer. Thyroid diseases are the most disorders of the endocrine system, affecting almost 13 million Americans.